P. Sathyanarayana

Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling

R. Berria, J. Finlayson, L. Mandarino, 2011, Diabetologia.

ANTIOXIDANT ACTIVITY SCREENING MODELS AND THEIR MECHANISM: A REVIEW

G. Arya, P. Sathyanarayana, Ranu Shukla, 2021 .

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

R. Muthupillai, S. Samson, M. Bajaj, 2011, Diabetologia.

NF-kappaB-inducing kinase (NIK) mediates skeletal muscle insulin resistance: blockade by adiponectin.

S. Choudhary, M. Bajaj, R. Tilton, 2011, Endocrinology.

Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes

R. Muthupillai, S. Samson, M. Bajaj, 2011, Obesity.

The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes.

Y. Birnbaum, Y. Ye, M. Bajaj, 2012, Atherosclerosis.

Effect of short-term free Fatty acids elevation on mitochondrial function in skeletal muscle of healthy individuals.

R. DeFronzo, V. Centonze, F. Folli, 2010, The Journal of clinical endocrinology and metabolism.

Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes

R. Muthupillai, S. Samson, M. Bajaj, 2011, Obesity.